{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cuvier V"],"funding":["Agence Nationale de la Recherche"],"pagination":["2270-2279"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6138490"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["84(10)"],"pubmed_abstract":["<h4>Aims</h4>The peptide nangibotide is the first clinical-stage agent targeting the immunoreceptor TREM-1 (triggering receptor expressed on myeloid cells-1) and is being investigated as a novel therapy for acute inflammatory disorders such as septic shock. This first-in-man, randomized, double-blind, ascending dose, placebo-controlled Phase I study evaluated the safety, tolerability and pharmacokinetics of nangibotide.<h4>Methods</h4>Twenty-seven healthy subjects (aged 18-45 years) were randomized into eight groups. Nangibotide was administered as a single continuous intravenous infusion. The first two groups received a single i.v. dose of 1 and 10 mg, respectively, over 15 min. Subsequent groups were randomized in a product : placebo ratio of 3:1 at doses ranging from 0.03 to 6 mg kg<sup"],"journal":["British journal of clinical pharmacology"],"pubmed_title":["A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition."],"pmcid":["PMC6138490"],"funding_grant_id":["ANR-15-RHU-0004"],"pubmed_authors":["Delor I","Lorch U","Cuvier V","Salcedo-Magguilli M","Olivier A","Witte S","Gibot S","Derive M","Garaud JJ"],"additional_accession":[]},"is_claimable":false,"name":"A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.","description":"<h4>Aims</h4>The peptide nangibotide is the first clinical-stage agent targeting the immunoreceptor TREM-1 (triggering receptor expressed on myeloid cells-1) and is being investigated as a novel therapy for acute inflammatory disorders such as septic shock. This first-in-man, randomized, double-blind, ascending dose, placebo-controlled Phase I study evaluated the safety, tolerability and pharmacokinetics of nangibotide.<h4>Methods</h4>Twenty-seven healthy subjects (aged 18-45 years) were randomized into eight groups. Nangibotide was administered as a single continuous intravenous infusion. The first two groups received a single i.v. dose of 1 and 10 mg, respectively, over 15 min. Subsequent groups were randomized in a product : placebo ratio of 3:1 at doses ranging from 0.03 to 6 mg kg<sup","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Oct","modification":"2025-04-22T06:46:08.106Z","creation":"2019-10-11T07:16:07Z"},"accession":"S-EPMC6138490","cross_references":{"pubmed":["29885068"],"doi":["10.1111/bcp.13668"]}}